Lyra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Portfolio Pulse from Benzinga Insights
Lyra Therapeutics (NASDAQ:LYRA) has received mixed ratings from analysts, with a notable decrease in the average 12-month price target by 43.69%. Analysts have provided a range of price targets from $0.50 to $12.00, reflecting varied expectations. The company's financial metrics show positive revenue growth but challenges in profitability and asset utilization.
June 20, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Lyra Therapeutics has received mixed ratings from analysts, with a significant decrease in the average price target by 43.69%. The company's financials show positive revenue growth but challenges in profitability and asset utilization.
The significant decrease in the average price target by 43.69% indicates a negative shift in analyst sentiment. Despite positive revenue growth, the company's challenges in profitability and asset utilization contribute to a bearish outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100